drugset
drugset / Trial / NCT03034304

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

NCT03034304 ↗

Phase 1 Terminated 105 enrolled HRYZ Biotech Co.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate Safety and tolerability of MASCT-I in patients with advanced solid tumors, either alone or in combination with chemical drugs or in combination with PD1 antibody.

Timeline

Start
2017-02-22
Primary completion
2023-11-13
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Cisplatin Other / unclassified 70 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Ifosfamide Small molecule 2 g Intravenous
Subject MASCT-I Cell therapy — —

Indications

cancer